Skip to main
AUTL
AUTL logo

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is positioned for long-term financial growth through anticipated improvements in manufacturing efficiency, which could lead to gross margins reaching 60-70%. The strong efficacy and safety data demonstrated in the pivotal FELIX study, coupled with a positive opinion from the CHMP, provide a solid foundation for the approval and commercialization of its innovative T-cell therapies. While market potential may face challenges due to the high costs of CAR-T therapies, the company's advancements in product development indicate a commitment to addressing these challenges effectively.

Bears say

Autolus Therapeutics faces challenges in its financial outlook, primarily due to anticipated stagnant sales in Q3 2025 attributed to changes in CMS reimbursement policies, leading to a potential underperformance in CAR-T therapeutic production. The company's management projects overhead costs to stabilize at around 500 patients annually, resulting in limited scalability since additional patient intake only increases material and labor costs. Furthermore, the presence of known adverse events such as cytokine release syndrome, neurotoxicity, and severe cytopenias may further hinder the widespread adoption and market potential of its CAR-T therapies.

Autolus Therapeutics (AUTL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.